Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
- Friday, June 10, 2022, 7:14
- PR Newswire
- Add a comment
Updated results for talquetamab monotherapy and in combination with daratumumab highlighted in oral presentations at the 2022 EHA Annual Congress VIENNA, June 10, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1…
About the Author
admin has written 21729 stories on this site.